Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
Home
Poster Schedule
All Days
Tue, May 14
Wed, May 15
Poster Schedule
Type here to filter the list
Tuesday, May 14, 2024
10:30 AM – 11:30 AM
PT
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Favorite
10:30 AM – 11:30 AM
PT
(T1030-01-02) Demonstrating the Excipient Effect In Vitro for Pre-clinical Formulation Analysis
Favorite
10:30 AM – 11:30 AM
PT
(T1030-01-03) Stability of Therapeutic Monoclonal Antibodies during Infusion with Elastomeric Pumps Intended for Home-Based Therapy
Favorite
10:30 AM – 11:30 AM
PT
(T1030-01-05) Flash Nanoprecipitation Permits Self-assembly of Ionizable Lipid Nanoparticles for Nucleic Acid Delivery
Favorite
10:30 AM – 11:30 AM
PT
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Favorite
10:30 AM – 11:30 AM
PT
(T1030-02-07) Analytical Method Validation Strategy for Determination of Charge Heterogeneity of Antibody Therapeutics Using Reference Material Comparison as an Alternative to Spiking Studies
Favorite
10:30 AM – 11:30 AM
PT
(T1030-02-08) Single Cell Gel Electrophoresis to Detect Genotoxicity of Iminostilbene, a Process Induced Impurity of Carbamazepine
Favorite
10:30 AM – 11:30 AM
PT
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Favorite
10:30 AM – 11:30 AM
PT
(T1030-02-10) Synthesis a Cationic-Polymer Incorporating Carboxylesterase Active Ester for the Delivery of CRISPR/Cas9 to Ameliorate Hyperlipidemia
Favorite
10:30 AM – 11:30 AM
PT
(T1030-02-11) The Importance of Orthogonal Methods for the Determination of the Size Distribution of Lipid Nanoparticles
Favorite
11:30 AM – 12:30 PM
PT
(T1130-02-06) Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Favorite
11:30 AM – 12:30 PM
PT
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Favorite
11:30 AM – 12:30 PM
PT
(T1130-02-08) Intestinal Organoid as a Predictive Model for the Assessment of Nano-Drug Delivery Systems
Favorite
11:30 AM – 12:30 PM
PT
(T1130-02-10) A Novel Approach to Mechanical Characterization of Pharmaceutical Lyospheres
Favorite
11:30 AM – 12:30 PM
PT
(T1130-02-11) Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Favorite
11:30 AM – 12:30 PM
PT
(T1130-02-09) Evaluation of Sample Preparation Techniques for Protein Quantification
Favorite
12:30 PM – 1:30 PM
PT
(T1230-01-01) Parallel-Competitive Absorption Metabolism Model for Calculation of Subcutaneous Bioavailability of Monoclonal Antibodies
Favorite
12:30 PM – 1:30 PM
PT
(T1230-01-04) Iontophoretic Transdermal Delivery of a Bioactive Molecule: Comparison of Nanoliposomal Platforms with Passive Delivery
Favorite
12:30 PM – 1:30 PM
PT
(T1230-01-05) Development of Inhalable Polymeric Nanoemulsions for Delivery of Gene Silencing Therapeutics in Lung Tumors
Favorite
12:30 PM – 1:30 PM
PT
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Favorite
12:30 PM – 1:30 PM
PT
(T1230-02-07) A Validated Immunocapture LC-MS/MS Hybrid Assay for the Quantitation of a Novel Multi-Domain Therapeutic Protein in Human Plasma with Clinical Sample Analysis
Favorite
12:30 PM – 1:30 PM
PT
(T1230-02-08) Quantitation of Soluble Tumor-Associated Antigens (sTAA) in Tumor Interstitial Fluid (TIF) Isolated from Frozen Solid Tumors
Favorite
12:30 PM – 1:30 PM
PT
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Favorite
12:30 PM – 1:30 PM
PT
(T1230-02-10) Development of a Highly Sensitive Immunoassay to Measure Circulating Levels of a Nanobody-Based Imaging Agent
Favorite
12:30 PM – 1:30 PM
PT
(T1230-02-11) Sensitive Quantitation of Antisense Oligonucleotides Using Capitainer
®
qDBS Microsampling Device Coupled with Hybridization LC-MS/MS
Favorite
1:30 PM – 2:30 PM
PT
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Favorite
1:30 PM – 2:30 PM
PT
(T1330-01-02) Formulation Development and Characterization of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine with a Toll-Like Receptor 7 Agonist
Favorite
1:30 PM – 2:30 PM
PT
(T1330-01-03) Stain-Free Approach to Determine and Monitor Cell Heath Using Supervised and Unsupervised Image-Based Deep Learning
Favorite
1:30 PM – 2:30 PM
PT
(T1330-01-04) Predicting the Aggregation Behavior of Liposomes Using Thermal Analysis
Favorite
1:30 PM – 2:30 PM
PT
(T1330-01-05) Optimizing Lipid Nanoparticles (LNPs) Processing for siRNA Delivery by Microfluidics System
Favorite
1:30 PM – 2:30 PM
PT
(T1330-02-06) Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Favorite
1:30 PM – 2:30 PM
PT
(T1330-02-07) Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Favorite
1:30 PM – 2:30 PM
PT
(T1330-02-08) Production and Characterization of Critical Biotin and DIG Conjugated RESCA-Anti-CD8 VHH Reagents to Enable the Non-Clinical and Clinical Anti-Drug Antibody Assay Development
Favorite
1:30 PM – 2:30 PM
PT
(T1330-02-10) Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Favorite
1:30 PM – 2:30 PM
PT
(T1330-02-11) Oligonucleotide Dual Hybridization Assay Using Offline Pre-incubation followed by an Automated Microfluidic Method
Favorite
1:30 PM – 2:30 PM
PT
(T1330-02-09) Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Favorite
2:30 PM – 3:30 PM
PT
(T1430-01-01) Static Light Scattering Signatures Used to Identify and Minimize Aggregation During Formulation Development
Favorite
2:30 PM – 3:30 PM
PT
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Favorite
2:30 PM – 3:30 PM
PT
(T1430-01-04) Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
Favorite
2:30 PM – 3:30 PM
PT
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Favorite
2:30 PM – 3:30 PM
PT
(T1430-02-07) Analysis of Glucagon-Like Peptide-1 (GLP-1) Analog in Rat Plasma Using an LC-MS/MS Workflow
Favorite
2:30 PM – 3:30 PM
PT
(T1430-02-08) Leveraging Buprenorphine as a Tool Molecule to Develop a Novel PBPK Model Accounting for Intestinal Lymphatic Absorption
Favorite
2:30 PM – 3:30 PM
PT
(T1430-02-09) Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Favorite
2:30 PM – 3:30 PM
PT
(T1430-02-10) A Novel In Vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards
Favorite
2:30 PM – 3:30 PM
PT
(T1430-01-02) Enhanced Transdermal Delivery of Anticancer Agent: A Comprehensive Study on Fractional Ablative Laser
Favorite
3:30 PM – 4:30 PM
PT
(T1530-02-06) Development of an Electrochemiluminescent Assay for the Detection of Anti-PEG IgE Antibodies in Human Serum
Favorite
3:30 PM – 4:30 PM
PT
(T1530-02-07) Integrated HypoSkin® Model and PBPK Modeling as a Bioavailability Predicting Tool for Subcutaneous Delivery of Protein Therapeutics
Favorite
3:30 PM – 4:30 PM
PT
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Favorite
3:30 PM – 4:30 PM
PT
(T1530-02-09) False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Favorite
3:30 PM – 4:30 PM
PT
(T1530-02-10) Development of a Generic, Automated, Microfluidic Human IgG-FcRn Affinity Assay In-Solution for Use in Antibody Engineering
Favorite
3:30 PM – 4:30 PM
PT
(T1530-02-11) Formulation Development and Characterization of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine with CpG Oligonucleotide
Favorite
